@prefix dcat: <http://www.w3.org/ns/dcat#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix vcard: <http://www.w3.org/2006/vcard/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://rec.harvest-normandie.data4citizen.com/dataset/oai-hal-tel-00863639v1> a dcat:Dataset ;
    dct:description """
              CD20 is a validated target for the immunotherapy of B lymphoid neoplasms, including ChronicLymphocytic Leukemia (CLL). We compared the activities of rituximab and GA101 (novel anti-CD20 antibody)on fresh human CLL cells in vitro. AnnexinV staining demonstrated induction of apoptosis after exposure torituximab or GA101. Unlike rituximab, GA101 induced a reduction of the mitochondrial transmembranepotential, an effect which could be partially inhibited by cyclosporin A and which was partially caspasedependent.GA101 was also found to induce the production of Reactive Oxygen Species. Analysis of pro- andanti-apoptotic protein content after exposure to antibodies demonstrated a strong degree of heterogeneity between samples. Bax underwent conformational activation and mitochondrial translocation upon exposure toantibodies in a caspase-independent manner. GA101 but not rituximab induced cleavage of caspase-8, -9 and -3.By transfecting CLL cells with anti-Bcl-xL siRNA using a sonoporation method, we found that reduction of BclxLcontent was associated with increased sensitivity to these antibodies. Our results suggest that apoptoticsignalization pathways differ between rituximab and GA101 with a greater involvement of the mitochondrialpathway for GA101. Inhibition of Bcl-xL could constitute an approach to sensitize CLL cells to the apoptoticeffects of anti-CD20 antibodies.
            """ ;
    dct:identifier "NNT: 2010LYO10346" ;
    dct:issued "2026-05-09T16:46:06.357213"^^xsd:dateTime ;
    dct:language "en" ;
    dct:modified "2026-05-09T16:46:06.357218"^^xsd:dateTime ;
    dct:publisher <https://rec.harvest-normandie.data4citizen.com/organization/cce9db95-46d9-4dc2-84b6-764215d0a002> ;
    dct:title "Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia" ;
    dcat:contactPoint [ a vcard:Organization ;
            vcard:fn "CCSD" ] ;
    dcat:distribution <https://rec.harvest-normandie.data4citizen.com/dataset/oai-hal-tel-00863639v1/resource/6b6dccf2-0f5a-40e0-b8c3-7d191936a8d6> ;
    dcat:keyword "apoptose",
        "apoptosis",
        "chronic-lymphocytic-leukemia",
        "ga101",
        "infoeu-reposemanticsdoctoralthesis",
        "leucemie-lymphoide-chronique",
        "rituximab",
        "sdvmheplife-sciences-q-biohuman-health-and-pathology",
        "sonoporation",
        "theses" ;
    dcat:landingPage <https://theses.hal.science/tel-00863639> .

<https://rec.harvest-normandie.data4citizen.com/dataset/oai-hal-tel-00863639v1/resource/6b6dccf2-0f5a-40e0-b8c3-7d191936a8d6> a dcat:Distribution ;
    dct:format "HTML" ;
    dct:issued "2026-05-09T16:46:06.360307"^^xsd:dateTime ;
    dct:modified "2026-05-09T16:46:06.346383"^^xsd:dateTime ;
    dct:title "Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia" ;
    dcat:accessURL <https://theses.hal.science/tel-00863639> .

<https://rec.harvest-normandie.data4citizen.com/organization/cce9db95-46d9-4dc2-84b6-764215d0a002> a foaf:Agent ;
    foaf:name "test_moissonnage_selune" .

<https://theses.hal.science/tel-00863639> a foaf:Document .